Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 3 Next >
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Appoints New Chief Executive Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Granted FDA Fast Track Designation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Receives $3.4 Million in Non-Dilutive Funding
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS